Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Debra L. Richardson

doi:10.1016/j.gore.2023.101148

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Debra L. Richardson

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended eye care strategies.

Original language	English (US)
Article number	101148
Journal	Gynecologic Oncology Reports
Volume	46
DOIs	https://doi.org/10.1016/j.gore.2023.101148
State	Published - Apr 2023
Externally published	Yes

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.gore.2023.101148

Cite this

@article{6f62cbae22e945598d307ec192c65535,

title = "Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology",

abstract = "Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended eye care strategies.",

author = "Richardson, {Debra L.}",

note = "Funding Information: Declaration of Competing Interests: Debra L Richardson reports honoraria for consulting for Immunogen, Mersana, GlaxoSmithKline and AstraZeneca. Her institution also receives research funding from Immunogen. Publisher Copyright: {\textcopyright} 2023 The Author",

year = "2023",

month = apr,

doi = "10.1016/j.gore.2023.101148",

language = "English (US)",

volume = "46",

journal = "Gynecologic Oncology Reports",

issn = "2211-338X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

AU - Richardson, Debra L.

N1 - Funding Information: Declaration of Competing Interests: Debra L Richardson reports honoraria for consulting for Immunogen, Mersana, GlaxoSmithKline and AstraZeneca. Her institution also receives research funding from Immunogen. Publisher Copyright: © 2023 The Author

PY - 2023/4

Y1 - 2023/4

N2 - Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended eye care strategies.

AB - Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended eye care strategies.

UR - http://www.scopus.com/inward/record.url?scp=85150855181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150855181&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2023.101148

DO - 10.1016/j.gore.2023.101148

M3 - Article

C2 - 37033209

AN - SCOPUS:85150855181

SN - 2211-338X

VL - 46

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

M1 - 101148

ER -

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this